ADRN-12/LEADS (Longitudinal Endotyping of Atopic Dermatitis Through Transcriptomic Skin Analysis) Request More Information Trial Objective Eczema (atopic dermatitis) is typically classified as mild, moderate or severe. In this trial, researchers are studying gene expression for the varying severity levels of eczema in order to guide new and improved treatments strategies and more personalized treatments. Skin samples from participants will be collected using a specialized, noninvasive dermatologic skin tape. People with and without eczema are needed for this trial. Enrollment Active Clinical Trials Currently Recruiting Who Can Participate Adults ages 18 and older and kids ages 6 to 17 with and without eczema. Age: 6-65 Gender: Any Gender Estimated Time Commitment 7-8 clinic visits over five to six months. × Payments are intended to compensate the participant for their time and effort during the study. Payments are typically given to the participant at the end of each completed study visit. Reimbursements are intended to compensate the participant for travel-related expenses. They must be approved by the study staff and require you to turn in receipts. Travel reimbursement will vary from study to study. Payment & Reimbursement Payment: Provided Travel Reimbursement: Available Trial Contact For more information, contact: Trish Taylor 303-398-1067 Request More Information Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors National Institutes of Health Principal Investigators Donald Leung, PhD, MD + × Donald Leung, PhD, MD Distinguished Professor Head, Division of Pediatric Allergy & Immunology Department of Pediatrics Edelstein Family Chair in Pediatric Allergy and Clinical Immunology View Full Profile Make an Appoinment Mark Boguniewicz, MD + × Mark Boguniewicz, MD Professor Division of Pediatric Allergy & Clinical Immunology Department of Pediatrics View Full Profile Patient Rating 4.8 out of 5 stars Make an Appoinment Request More Information By completing this form, you agree to learn more about this study and see if you qualify. First Name:* Last Name:* Email Address:* Phone:* I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: YesNo
Trial Objective Eczema (atopic dermatitis) is typically classified as mild, moderate or severe. In this trial, researchers are studying gene expression for the varying severity levels of eczema in order to guide new and improved treatments strategies and more personalized treatments. Skin samples from participants will be collected using a specialized, noninvasive dermatologic skin tape. People with and without eczema are needed for this trial.